- Home
- LUXE vs EWTX Comparison
LUXE vs EWTX Comparison
Compare LUXE & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUXE
- EWTX
- Stock Information
- Founded
- LUXE 1987
- EWTX 2017
- Country
- LUXE Germany
- EWTX United States
- Employees
- LUXE N/A
- EWTX N/A
- Industry
- LUXE
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- LUXE
- EWTX Health Care
- Exchange
- LUXE NYSE
- EWTX Nasdaq
- Market Cap
- LUXE 1.0B
- EWTX 1.2B
- IPO Year
- LUXE N/A
- EWTX 2021
- Fundamental
- Price
- LUXE $7.91
- EWTX $13.35
- Analyst Decision
- LUXE
- EWTX Buy
- Analyst Count
- LUXE 0
- EWTX 9
- Target Price
- LUXE N/A
- EWTX $39.89
- AVG Volume (30 Days)
- LUXE 109.6K
- EWTX 983.7K
- Earning Date
- LUXE 05-14-2025
- EWTX 08-07-2025
- Dividend Yield
- LUXE N/A
- EWTX N/A
- EPS Growth
- LUXE N/A
- EWTX N/A
- EPS
- LUXE N/A
- EWTX N/A
- Revenue
- LUXE $962,367,055.00
- EWTX N/A
- Revenue This Year
- LUXE $38.43
- EWTX N/A
- Revenue Next Year
- LUXE $93.30
- EWTX N/A
- P/E Ratio
- LUXE N/A
- EWTX N/A
- Revenue Growth
- LUXE 8.74
- EWTX N/A
- 52 Week Low
- LUXE $3.22
- EWTX $10.60
- 52 Week High
- LUXE $12.50
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- LUXE N/A
- EWTX 34.22
- Support Level
- LUXE N/A
- EWTX $12.15
- Resistance Level
- LUXE N/A
- EWTX $14.85
- Average True Range (ATR)
- LUXE 0.00
- EWTX 0.68
- MACD
- LUXE 0.00
- EWTX -0.16
- Stochastic Oscillator
- LUXE 0.00
- EWTX 23.13
About LUXE LUXEXPERIENCE B.V. SPON ADS EACH RE SPON ADS EACH REP 1 ORD SHS
LuxExperience BV is the digital, multi-brand luxury group and the online shopping destination for luxury enthusiasts. The group operates a portfolio of some of the distinguished store brands in digital luxury and creates communities for luxury enthusiasts with digital and physical experiences. Its brands are MYTHERESA, NET-A-PORTER, MR PORTER, YOOX, and THE OUTNET.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.